Novavax COVID-19 vaccine, recently cleared by U.S. regulators, was tested at UW
A protein-based COVID-19 vaccine that went through clinical trials at the UW Medicine Virology Research Clinic could soon be available in the U.S. The Food and Drug Administration this week authorized Novavax’s vaccine for emergency use in adults 18 and older. A green light from the Centers for Disease Control and Prevention is needed before Americans can get the two-dose vaccination.
Dr. Scott McClelland, Professor of Medicine, of Global Health, and of Epidemiology at UW, is quoted.